Dr. Gobeil obtained her B.Sc. in Biochemistry from Université de Montréal (2009) and completed a doctoral degree (2016) in enzyme engineering under the supervision of Prof. Joelle Pelletier at the Université de Montréal. She then joined the laboratory of Dr. Spicer at Duke University in the Biochemistry Department where her work aimed at combining structural and biophysical tools to develop fungal-selective therapeutic agents.
In March 2020, while the COVID-19 pandemic was beginning, Dr. Gobeil joined the Duke Human Vaccine Institute (DHVI) - Division of structural biology, led by Dr. Priyamvada Acharya where she used cryogenic electron microscopy (Cryo-EM) to unravel how the structure, function, and antigenicity of the SARS-CoV-2 spike protein was impacted by the naturally occurring mutations in the arising variants.
Dr. Gobeil is a member of PROTEO (The Quebec Network for Research on Protein Function, Engineering, and Applications) and CRI (Université Laval Infectious Disease Research Center). She also hold the Tier 2 Canadian Research Chair in Structural Systems Biology.
Dr. Gobeil research interests lie in using a fundament structural biology approach to tackle clinically relevant problems in the infectious disease realm for protein engineering, and drug design applications.
Offline Website Builder